2025-09-04 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the provided data, presented in a structured report.

## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (LLY):** 221.03%
*   **Cumulative Return (VOO):** 99.17%
*   **Absolute Divergence:** 118.86
*   **Relative Divergence:** 43.1% (Compared to the historical min/max divergence range, the current divergence sits at the 43.1 percentile)

**Analysis:** LLY has significantly outperformed the S&P 500.  The relative divergence of 43.1% indicates that the current level of outperformance, while substantial, is within the lower half of its historical range relative to VOO. This suggests that while LLY has done exceptionally well, there might be potential for further divergence or a period of consolidation.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
| ---------- | ------ | ------ | ------ | ----- | ------ |
| 2015-2017  | 10.0%  | 56.3%  | -19.0% | 0.0   | 75.7   |
| 2016-2018  | 39.0%  | 58.6%  | 21.0%  | -0.1  | 103.7  |
| 2017-2019  | 50.0%  | 58.6%  | 20.0%  | 0.3   | 117.8  |
| 2018-2020  | 52.0%  | 58.6%  | 33.0%  | 0.1   | 151.4  |
| 2019-2021  | 106.0% | 60.6%  | 57.0%  | 0.2   | 247.6  |
| 2020-2022  | 98.0%  | 64.8%  | 96.0%  | 0.2   | 328.0  |
| 2021-2023  | 133.0% | 64.8%  | 115.0% | 0.3   | 522.6  |
| 2022-2024  | 150.0% | 72.2%  | 124.0% | 0.2   | 692.1  |
| 2023-2025  | 74.0%  | 76.8%  | 23.0%  | 0.2   | 658.9  |

**Analysis:**

*   **CAGR:**  LLY has demonstrated impressive growth rates over various periods, with the most recent (2022-2024) showing a very high CAGR of 150%. However, the most recent period (2023-2025) shows a drop to 74.0%, indicating potential slowing growth.
*   **MDD:** Maximum Drawdown has increased over time, recently going as high as 76.8%, suggesting higher risk and volatility.
*   **Alpha:**  Positive Alpha values consistently demonstrate LLY's ability to generate returns above the market benchmark, with the most recent periods showing extremely high alpha.
*   **Beta:** Beta values consistently near zero indicate that LLY's price movements are largely uncorrelated with the overall market.
*   **Cap:** The market capitalization has dramatically increased, reflecting strong investor confidence.

### 2. Recent Price Action

*   **Current Price:** 735.01
*   **Last Market Data:** Price: 734.9, Previous Close: 735.19, Change: -0.04
*   **5-Day Moving Average:** 733.95
*   **20-Day Moving Average:** 699.6455
*   **60-Day Moving Average:** 755.5103

**Analysis:** The current price is slightly below the previous close, indicating a minor pullback.  The price is above the 5-day and 20-day moving averages, suggesting an upward trend in the short to medium term. However, the price is below the 60-day moving average, indicating a potential longer-term resistance level. The minor negative change from the last market doesn't indicate any significant immediate issue.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3403 (Low Risk)
*   **RSI:** 83.47 (Overbought)
*   **PPO:** 1.1216
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Recent (20-day) Relative Divergence Change:** 2.3 (+)  (Short-term increase)
*   **Expected Return (%):** 212.6% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** The low MRI suggests a stable market environment for LLY.
*   **RSI:** The high RSI value indicates that the stock is overbought, suggesting a potential pullback or consolidation in the short term.
*   **PPO:** Positive PPO value indicates that the 20-day EMA is above the 200-day EMA, confirming the bullish trend.
*   **Hybrid Signal:** Recommends to Buy 80% of cash(1 share) with caution because of the MRI indicator. Also recommends monthly investment.
*   **Recent Divergence Change:** The recent increase in relative divergence further confirms the recent outperformance.
*   **Expected Return:** The extremely high expected return suggests a very positive outlook for long-term investors, anticipating significant outperformance compared to the S&P 500.

### 4. Recent News & Significant Events

*   **Volatility:** Recent stock volatility influenced by news, earnings, or executive actions.
*   **Analyst Discussion:**  Analysts are actively discussing LLY's performance and outlook.
*   **Major Business Developments:** Recent headlines regarding business developments, regulatory changes, or market events.
*   **Risk & Opportunity:** Market experts highlight both risks and opportunities, advising investors to stay informed.

**Analysis:** The news indicates that LLY is subject to considerable market attention and volatility.  Investors should closely monitor news and company announcements to understand the drivers behind these movements.

### 5. Recent Earnings Analysis

| 날짜         | EPS    | 매출         |
| ------------ | ------ | ------------ |
| 2025-08-07 | 6.3    | 15.56 B$      |
| 2025-05-01 | 3.07   | 12.73 B$      |
| 2024-10-30 | 1.08   | 11.44 B$      |
| 2024-08-08 | 3.29   | 11.30 B$      |
| 2025-08-07 | 3.29   | 11.30 B$      |

**Analysis:** Earnings Per Share (EPS) and Revenue have generally increased over the reported periods, suggesting strong financial performance.  The recent EPS of 6.3 is particularly noteworthy.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | ------------- |
| 2025-06-30 | $15.56B    | 84.27%        |
| 2025-03-31 | $12.73B    | 82.53%        |
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |
| 2024-06-30 | $11.30B    | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE         |
| ------------ | ---------- | ----------- |
| 2025-06-30 | $18.27B    | 30.98%      |
| 2025-03-31 | $15.76B    | 17.50%      |
| 2024-12-31 | $14.19B    | 31.07%      |
| 2024-09-30 | $14.24B    | 6.81%       |
| 2024-06-30 | $13.56B    | 21.88%      |

**Analysis:** Revenue and Profit Margin have shown consistent growth, indicating efficient management and strong demand for LLY's products. Equity has increased, and Return on Equity (ROE) is fluctuating but generally high, reflecting the company's ability to generate profits from shareholders' investments.

### 7. Overall Analysis & Recommendation

Eli Lilly and Co (LLY) presents a compelling picture of strong financial performance, market outperformance, and positive future prospects.

*   **Strengths:**  High growth, significant outperformance of the S&P 500, strong earnings, increasing revenue and profit margins, high ROE, positive long-term expected return.

*   **Weaknesses:**  High RSI suggests a possible short-term pullback, increasing MDD indicates higher risk and volatility, subject to news-driven volatility.

**Recommendation:**

LLY appears to be a promising investment for the long term. The strong financial performance, market outperformance, and positive future outlook support a bullish stance. The high RSI suggests caution in the short term, and investors may consider waiting for a pullback before initiating or adding to their positions. Monitoring news and company announcements is crucial to understanding and managing the stock's volatility.
